missions. Often it is mentioned that in order to obtain unbiased estimates based on indirect comparisons the distribution of characteristics of the patients included in the different trials needs to be similar, as well as the study design. By means of directed acyclic graphs (DAGs), which are often used in epidemiology for inferences, it is explained that indirect and mixed treatment comparisons are biased when differences in patient characteristics and trial design do act as an effect modifier of the treatment effect. Furthermore, the graphs can be used to differentiate between heterogeneity, selection, and confounding bias. DAGs for indirect comparisons of RCTs are compared with DAGs for head-to-head randomized designs and meta-analysis of RCTs. 
PMC3 METHODS FOR ESTIMATING CONFIDENCE INTERVALS OF PER MEMBER PER MONTH (PMPM) UTILIZATION RATES
and ($227.74, $259.99) , respectively. The PMPM estimate of hospital days was 0.108 days: Fieller and MC 95% confidence intervals were (0.098, 0.118) and (0.100, 0.116), respectively. The PMPM point estimate for number of hospital admissions was 0.0137: Fieller and MC 95% confidence intervals were (0.0131, 0.0142) and (0.0133, 0.0142), respectively. CONCLUSION: The Fieller and MC simulation methods produced similar confidence intervals for PMPM estimates for each of the outcomes of interest. Use of these methods would improve the utility of PMPM point estimates in comparing health care technologies.
PMC4 THE ADOPTION AND DIFFUSION OF COST-EFFECTIVENESS ACCEPTABILITY CURVES IN PUBLISHED ECONOMIC EVALUATIONS
Greenberg D 1 , Cohen JT 2 , Neumann PJ 2 1 Ben-Gurion University of the Negev, Beer-Sheva, Israel, 2 Tufts-New England Medical Center, Boston, MA, USA Cost-effectiveness acceptability curves (CEACs) plot the probability that one treatment is more cost-effective than another, as a function of a societal threshold willingness to pay for additional units of efficacy (e.g., life-year or QALY gained). OBJEC-TIVES: To assess the adoption and diffusion rates of CEACs within the field of economic evaluations. METHODS: We used the Tufts-New England Medical Center registry of 620 published cost-effectiveness analyses (CEA), presenting an original cost/ QALY ratio from 2002-2005 (http://www.tufts-nemc.org/ cearegistry/). For each CEA we recorded the year of publication, journal's name, study origin (country), and a subjective assessment of overall study quality ranging from 1 (low) to 7 (high). We used univariate analyses (chi-square and t-test), to assess differences in CEAC use by year of publication, study origin and quality. We also compared practices in journals publishing a high-volume (n Ն 10) versus low-volume (n < 10) of CEAs during the study period. We used multivariable logistic regression to identify factors predicting CEAC use. RESULTS: Approximately one fifth (20.2%) of CEAs presented a CEAC. The adoption of CEACs has increased over time from 5.3% (2002) to 30.4% (2005) (p < 0.0001). Studies using CEAC were of higher quality (4.6 Ϯ 1.0 vs.4.1 Ϯ 0.9; p < 0.0001) and more prevalent in high-volume journals (30.7% vs. 16.4%; p < 0.0001). CEACs were more frequently used in UK studies (48.8%) versus studies from Sweden (24.1%), The Netherlands (17.9%), United States (11.7%), and Canada (9.1%). Significant predictors for using CEACs were study quality (OR 1.96; 95% CI-1.53-2.51), publication in a high-volume journal (OR 1.85; 95% CI-1.18-2.89), and year of publication. CONCLUSIONS: CEACs have been rapidly adopted, especially among UK-based investigators. If CEACs turn out to be a useful tool to decision makers, this trend is encouraging, but means to achieve more rapid deployment should be identified.
PMC5 AN ANATOMY OF PHARMACEUTICAL COST-UTILITY ANALYSES, 1976-2005
Fang C, Cohen JT, Neumann PJ Tufts-New England Medical Center, Boston, MA, USA OBJECTIVE: To review and critically evaluate published costutility analysis (CUA) research on pharmaceuticals for the past three decades. METHODS: We examined data from the Tufts-NEMC Cost-Effectiveness Analysis Registry www.tuftsnemc.org/cearegistry), which contains detailed information on over 1100 CUAs and 3000 cost-utility ratios (in $US2005) published from 1976-2005. RESULTS: Of 1164 CUAs published through 2005, 518 (44.5%) pertain to pharmaceuticals. The proportion of all CUAs that focus on pharmaceuticals increased from 32% prior to 1990 to 48% from 1990-2005. U.S.-based investigators account for 53.6% of the total (47.5% of pharmaceutical studies), though the relative proportion of US-based studies has decreased over time. The U.K.'s share of total published CUAs increased from 7% in 1990 to 18% in 2005. The quality of study (as measured by a subjective 1-7 scale) did not differ by type of sponsorship (4.4 for industry vs. 4.55 for nonindustry, p = 0.44). The leading journals for publishing pharmaceutical CUAs were Pharmacoeconomics (58 CUAs), Ann Intern Med (47), Int J Technol Assess Health Care (37), JAMA (34) and Am J Med (25). About 38% of pharmaceutical CUAs were sponsored by pharmaceutical companies, 27% by non-industry sources (and in 35% the source of funding could not be determined). Pfizer (26), Norvatis (25), Schering Plough (23), GSK (21) and Roche (19) have funded the most pharmaceutical CUAs. The median of 1055 pharmaceutical CE ratios is $26,000/QALY and is lower for industry vs. non-industry funded studies (p = 0.004). In multivariate analysis adjusting for factors such as sponsor type, pharmaceutical CE ratios are similar to others-
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